Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | SCN4A | P35499 | 4/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17976091 | 1.00 | AOC3 (0.45) | AOC3ACHESLC6A4ACP3TAAR1 | |
| SCHEMBL5712566 | 0.87 | SLC6A4 (0.48) | SLC6A4SCN4AANPEPENPEP | |
| SCHEMBL12056788 | 0.84 | AOC3 (0.42) | AOC3ACHESLC6A4ACP3TAAR1 | |
| SCHEMBL28337687 | 0.84 | AOC3 (0.42) | AOC3ACHESLC6A4ACP3TAAR1 | |
| SCHEMBL28337706 | 0.84 | AOC3 (0.42) | AOC3ACHESLC6A4ACP3TAAR1 | |
| SCHEMBL4277230 | 0.83 | AOC3 (0.45) | AOC3ACHEACP3TAAR1TACR1 | |
| SCHEMBL18765644 | 0.82 | AOC3 (0.44) | AOC3ACHEACP3TAAR1TACR1 | |
| SCHEMBL4598026 | 0.82 | AOC3 (0.44) | AOC3ACHEACP3TAAR1TACR1 | |
| SCHEMBL30559594 | 0.82 | AOC3 (0.44) | AOC3ACHEACP3TAAR1TACR1 | |
| SCHEMBL20274525 | 0.82 | TAAR1 (0.47) | AOC3ACHEACP3TAAR1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-3335736-A1 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2016154135-A1 | ALKENE ISOMERIZATION AS AN ENTRY TO EFFICIENT ALTERNATING RING-OPENING METATHESIS POLYMERIZATION (i-AROMP) | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2016-09-29 | — | — | WO | disclosed |
| US-8513239-B2 | Chiral cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2010131145-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131146-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131147-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
| US-20090111789-A1 | CHIRAL CIS-IMIDAZOLINES | HOFFMANN-LA ROCHE, INC. | 2009-04-30 | — | — | US | disclosed |
| EP-0688679-B1 | Method for reversible thermosensitive recording | TOPPAN PRINTING CO LTD (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0418399-B1 | COMPOSITION FOR REVERSIBLE THERMAL RECORDING MEDIUM | TOPPAN PRINTING CO LTD (JP) | 1996-08-28 | — | — | EP | disclosed |
| EP-0688679-A1 | Method for reversible thermosensitive recording | Toppan Printing Co., Ltd. (JP) | 1995-12-27 | — | — | EP | disclosed |
| US-5178669-A | COMPOSITION FOR REVERSIBLE THERMAL RECORDING MEDIA | TOPPAN PRINTING CO., LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
| EP-0418399-A1 | COMPOSITION FOR REVERSIBLE THERMAL RECORDING MEDIUM | Toppan Printing Co., Ltd. (JP) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111789-A1 | CHIRAL CIS-IMIDAZOLINES | FOXM1, CCNE1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AOC3 3811/4885ACHE 3764/4885SLC6A4 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.